Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in pressure-overloaded rat heart

Kou Gi Shyu, Jer Young Liou, Bao Wei Wang, Wei Jen Fang, Hang Chang

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The use of β-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1α (HIF-1α) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1α in cardiac hypertrophy due to pressure overload and after treatment with β-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1α expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 ± 9 mmHg in the sham group to 94 ±5 mmHg (p <0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1α, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-β (NGF-β) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1α and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1α, VEGF and BNP increased and mRNA of NGF-β decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1α, VEGF, BNP, and NGF-β to the baseline values. Increased immunohistochemical labeling of HIF-1α, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1α, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-β mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1α,VEGF, BNP, and NGF-β in the hypertrophic myocardium.

Original languageEnglish
Pages (from-to)409-420
Number of pages12
JournalJournal of Biomedical Science
Volume12
Issue number2
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Hypoxia-Inducible Factor 1
Cardiomegaly
Vascular Endothelial Growth Factor A
Rats
Brain Natriuretic Peptide
Pressure
Nerve Growth Factor
Messenger RNA
Myocardium
Valsartan
Proteins
Weights and Measures
Labeling
Arterial Pressure
Body Weight
carvedilol
Doxazosin
Drug therapy
Echocardiography
Polymerase chain reaction

Keywords

  • Aortic banding
  • Cardiac hypertrophy
  • HIF-1α
  • Pressure overload
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in pressure-overloaded rat heart. / Shyu, Kou Gi; Liou, Jer Young; Wang, Bao Wei; Fang, Wei Jen; Chang, Hang.

In: Journal of Biomedical Science, Vol. 12, No. 2, 03.2005, p. 409-420.

Research output: Contribution to journalArticle

@article{532152a09ab64d3aaa968ba0ffe4c667,
title = "Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in pressure-overloaded rat heart",
abstract = "The use of β-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1α (HIF-1α) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1α in cardiac hypertrophy due to pressure overload and after treatment with β-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1α expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 ± 9 mmHg in the sham group to 94 ±5 mmHg (p <0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1α, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-β (NGF-β) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1α and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1α, VEGF and BNP increased and mRNA of NGF-β decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1α, VEGF, BNP, and NGF-β to the baseline values. Increased immunohistochemical labeling of HIF-1α, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1α, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-β mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1α,VEGF, BNP, and NGF-β in the hypertrophic myocardium.",
keywords = "Aortic banding, Cardiac hypertrophy, HIF-1α, Pressure overload, VEGF",
author = "Shyu, {Kou Gi} and Liou, {Jer Young} and Wang, {Bao Wei} and Fang, {Wei Jen} and Hang Chang",
year = "2005",
month = "3",
doi = "10.1007/s11373-005-3008-x",
language = "English",
volume = "12",
pages = "409--420",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "2",

}

TY - JOUR

T1 - Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in pressure-overloaded rat heart

AU - Shyu, Kou Gi

AU - Liou, Jer Young

AU - Wang, Bao Wei

AU - Fang, Wei Jen

AU - Chang, Hang

PY - 2005/3

Y1 - 2005/3

N2 - The use of β-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1α (HIF-1α) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1α in cardiac hypertrophy due to pressure overload and after treatment with β-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1α expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 ± 9 mmHg in the sham group to 94 ±5 mmHg (p <0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1α, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-β (NGF-β) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1α and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1α, VEGF and BNP increased and mRNA of NGF-β decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1α, VEGF, BNP, and NGF-β to the baseline values. Increased immunohistochemical labeling of HIF-1α, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1α, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-β mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1α,VEGF, BNP, and NGF-β in the hypertrophic myocardium.

AB - The use of β-blockers has emerged as a beneficial treatment for cardiac hypertrophy. Hypoxia-inducible factor-1α (HIF-1α) is tightly regulated in the ventricular myocardium. However, the expression of HIF-1α in cardiac hypertrophy due to pressure overload and after treatment with β-blocker is little known. To evaluate the effect of carvedilol on both myocardial HIF-1α expression and cardiac hypertrophy, infra-renal aortic banding was performed for 4 weeks in adult Sprague-Dawley rats to induce cardiac hypertrophy. Carvedilol at 50 mg/kg body weight per day after surgery was given. Heart weight and the ratio of heart weight and body weight increased significantly after aortic banding for 4 weeks in the absence of drug treatment. Mean arterial pressure increased from 80 ± 9 mmHg in the sham group to 94 ±5 mmHg (p <0.001) in the banding group. Echocardiography showed concentric hypertrophy after aortic banding. Mean arterial pressure decreased after treatment with carvedilol. The increased wall thickness and heart weight was reversed to normal by carvedilol. Western blot showed that HIF-1α, vascular endothelial growth factor (VEGF) and brain natriuretic peptide (BNP) proteins were up-regulated and nerve growth factor-β (NGF-β) down-regulated in the banding group. Treatment with valsartan, doxazosin, or N-acetylcysteine did not significantly affect HIF-1α and VEGF proteins expression in the banding groups. Real-time polymerase chain reaction showed that mRNA of HIF-1α, VEGF and BNP increased and mRNA of NGF-β decreased in the banding group. Treatment with carvedilol reversed both protein and mRNA of HIF-1α, VEGF, BNP, and NGF-β to the baseline values. Increased immunohistochemical labeling of HIF-1α, VEGF, and BNP in the ventricular myocardium was observed in the banding group and carvedilol again normalized the labeling. In conclusion, HIF-1α, VEGF, and BNP mRNA and protein expression were up-regulated, while NGF-β mRNA and protein was downregulated in the rat model of pressure-overloaded cardiac hypertrophy. Treatment with carvedilol is associated with a reversal of abnormal regulation of HIF-1α,VEGF, BNP, and NGF-β in the hypertrophic myocardium.

KW - Aortic banding

KW - Cardiac hypertrophy

KW - HIF-1α

KW - Pressure overload

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=21244479992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244479992&partnerID=8YFLogxK

U2 - 10.1007/s11373-005-3008-x

DO - 10.1007/s11373-005-3008-x

M3 - Article

C2 - 15942707

AN - SCOPUS:21244479992

VL - 12

SP - 409

EP - 420

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 2

ER -